<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Alanine aminotransferase (ALT) predicts incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM), possibly reflecting early <z:hpo ids='HP_0001397'>fatty liver</z:hpo> and hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> can improve <z:hpo ids='HP_0001397'>fatty liver</z:hpo> and hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>In the Canadian Normoglycemia Outcome Evaluation trial, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> (Rosi/Met, 4/1000 mg) reduced incident T2DM by 66% in subjects with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>For insight on the hepatic effects of this therapy in relation to T2DM, we evaluated the temporal changes in waist, hepatic insulin sensitivity (1/Homeostasis Model Assessment of <z:hpo ids='HP_0000855'>Insulin Resistance</z:hpo>) and ALT in the Rosi/Met (n = 103) and placebo (n = 104) arms over median of 3.9 years </plain></SENT>
<SENT sid="4" pm="."><plain>Waist did not differ between the arms </plain></SENT>
<SENT sid="5" pm="."><plain>Hepatic insulin sensitivity improved in the Rosi/Met arm in year 1, but deteriorated thereafter as in the placebo arm </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, Rosi/Met lowered ALT in year 1 and maintained this effect throughout the trial </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, low-dose Rosi/Met had no effect on central <z:hpo ids='HP_0001513'>obesity</z:hpo>, a transient effect on hepatic insulin sensitivity, and a sustained effect on ALT </plain></SENT>
</text></document>